Efficacy and safety of 1% terbinafine hydrochloride versus 2% sertaconazole cream in the treatment of tinea corporis

A. Sumitha, M. Geetha, G. H. Shashikala, H. S. Somashekar, K. S. Chandan


Background: Tinea corporis is a common superficial dermatophytosis seen in tropical countries. This study was done to compare the efficacy and safety of topical antifungal agents, terbinafine versus sertaconazole in the treatment of tinea corporis.

Methods: This study was conducted in Babuji Hospital and Chigateri Government Hospital, Davangere. A total of 60 (n=60) patients were included and divided into two groups of 30 patients each in the study. 1st group - received topical 1% terbinafine hydrochloride and 2nd group - received 2% sertaconazole cream. Patients were advised to apply cream twice daily for 4 weeks. Improvement in clinical parameters like erythema, scaling, itching, and potassium hydroxide (KOH) mount were taken for assessing the efficacy of drugs. They were followed-up at the end of 2, 4, and 6 weeks to assess the improvement of the condition. Complete cure rate was defined as mycological cure with a complete absence of clinical signs and symptoms. For safety data of both drugs presence of any local side effects (like stinging sensation, swelling and increased erythema) were analyzed in both groups. Statistical analysis was done using students paired t-test and unpaired t-test.

Results: When two groups were compared at the end of 2 weeks, complete cure rate for terbinafine was 80% as compared to 63.3% for sertaconazole (p<0.003). However,

at the end of 4 weeks, sertaconazole was as effective as terbinafine and statistically non-significant (p>0.05) results were obtained. KOH mount was negative in both groups at the end of 2nd week. Local side effects like erythema, swelling, stinging sensation were not noticed during the study in both the groups.

Conclusion: From this study, it was shown that 2% sertaconazole cream was as effective as 1% terbinafine cream, though 1% terbinafine had higher rates of complete cure at the end of 2 weeks as compared to sertaconazole.


Dermatophyte, Ringworm, Potassium hydroxide mount, Itching, Erythema

Full Text:



Eleswki BE, Hughey LC, Sobera JO, Hay R. Fungal diseases. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd Edition, Volume 2. USA: Elsevier; 2012: 1255-65.

Patel P, Mulla S, Patel D, Shrimali G. A study of superficial mycosis in south Gujarat region. Nat J Community Med. 2010;1(2):85-8.

van Heerden JS, Vismer HF. Tinea corporis/cruris: new treatment options. Dermatology. 1997;194 Suppl 1:14-8.

Susilo R, Korting HC, Strauss UP, Sertaconazole Study Group. Dermatomycoses of the glabrous skin: a double-blind, randomised, comparative trial of sertaconazole 2% cream once daily versus vehicle. Clin Drug Investig. 2003;23(6):387-94.

Budimulja U, Bramono K, Urip KS, Basuki S, Widodo G, Rapatz G, et al. Once daily treatment with terbinafine 1% cream (Lamisil) for one week is effective in the treatment of tinea corporis and cruris. A placebo-controlled study. Mycoses. 2001;44(7-8):300-6.

Choudhary S, Bisati S, Singh A, Koley S. Efficacy and safety of terbinafine hydrochloride 1% cream vs. sertaconazole nitrate 2% cream in tinea corporis and tinea cruris: a comparative therapeutic trial. Indian J Dermatol. 2013;58(6):457-60.

Lakshmi CP, Bengalorkor GM. Clinical efficacy of topical terbinafine versus topical luliconazole in treatment of tinea corporis/tineacruris patients. Br J Pharm Res. 2013;3(4):1001-14.

Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59.

Sharma A, Saple DG, Surjushe A, Rao GR, Kura M, Ghosh S, et al. Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis. Mycoses. 2011;54(3):217-22.

Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126 Suppl 39:2-7.

Tamilselvan A, Girisha G, Vijaybhaskar, Suthakaran R. Comparative evaluation of newer topical antifungal agents in the treatment of superficial fungal infections. Int Res J Pharm. 2013;4(6):224-8.